

# MARROW

ANNALS of THE NEW YORK  
ACADEMY OF SCIENCES

## Regulatory actions of 3',5'-cyclic adenosine monophosphate on osteoclast function: possible roles of Epac-mediated signalling

Journal:	<i>MARROW-Ann NY Acad Sci</i>
Manuscript ID	MARROW-046.R1
Manuscript Type:	Perspective
Date Submitted by the Author:	n/a
Complete List of Authors:	Jeevaratnam, Kamalan; University of Surrey, Faculty of Health and Medical Sciences; Perdana University - Royal College of Surgeons Ireland, School of Medicine Salvage, Samantha; University of Cambridge, Physiological Laboratory; University of Cambridge, Department of Biochemistry Li, Mengyi; University of Cambridge, Physiological Laboratory Huang, Christopher; University of Cambridge, Physiological Laboratory; University of Cambridge, Department of Biochemistry
Keywords:	cAMP, Epac, osteoclast, integrins, Rap1

SCHOLARONE™  
Manuscripts

***Perspective: Marrow (NYAS).***

***Regulatory actions of 3',5'-cyclic adenosine monophosphate on osteoclast function: possible roles of Epac-mediated signalling***

***Kamalan Jeevaratnam<sup>a,b</sup>, Samantha C. Salvage<sup>c,d</sup>, Mengye Li<sup>d</sup> and Christopher L.-H. Huang<sup>c,d</sup>***

<sup>a</sup>Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7AL, United Kingdom;

<sup>b</sup>School of Medicine, Perdana University - Royal College of Surgeons Ireland, 43400 Serdang, Selangor, Darul Ehsan, Malaysia;

<sup>c</sup>Department of Biochemistry, University of Cambridge, Hopkins Building, Cambridge, CB2 1QW, United Kingdom;

<sup>d</sup>Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG, United Kingdom.

Corresponding author: Christopher L.-H. Huang, Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG, United Kingdom. Email: [clh11@cam.ac.uk](mailto:clh11@cam.ac.uk).

Short title: Epac-mediated signalling in osteoclast function.

Key words: cAMP; Epac; osteoclast; integrins; Rap1

[3129 words]

**Abstract**

Alterations in cellular levels of the second messenger 3'-5'-cyclic adenosine monophosphate [cAMP]<sub>i</sub> regulate a wide range of physiologically important cellular signalling processes in numerous cell types. Osteoclasts are terminally differentiated, multinucleated cells specialised for bone resorption. Their systemic regulator, calcitonin, triggers morphometrically and pharmacologically distinct, retraction ('R') and quiescence ('Q'), effects respectively on cell-spread area and protrusion-retraction motility paralleling its inhibition of bone resorption. Q effects were reproduced by cholera toxin-mediated G<sub>s</sub>-protein activation known to increase [cAMP]<sub>i</sub>, unaccompanied by the [Ca<sup>2+</sup>]<sub>i</sub> changes contrastingly associated with R effects. We explore a hypothesis implicating cAMP-signalling involving guanine nucleotide-exchange activation of the small GTPase Ras-proximate-1 (Rap1) by exchange proteins directly activated by cAMP (Epac). Rap1 activates integrin clustering, cell adhesion to bone matrix, associated cytoskeletal modifications and signalling processes, and transmembrane transduction functions. Epac activation enhanced, whereas Epac inhibition or shRNA-mediated knockdown compromised the appearance of markers for osteoclast differentiation and motility following receptor activator of nuclear factor kappa-B ligand (RANKL) stimulation. Deficiencies in talin and Rap1 compromised in vivo bone resorption producing osteopetrotic phenotypes in genetically modified murine models. Translational implications for an Epac-Rap1 signalling hypothesis in relationship to N-bisphosphonate actions on prenylation and membrane localisation of small GTPases are discussed.

### ***3'-5'-cyclic adenosine monophosphate in the regulation of specialised cell types***

Alterations in cellular levels of the key second messenger 3'-5'-cyclic adenosine monophosphate [cAMP]<sub>i</sub> take place with alterations in the balance between its generation and hydrolysis. The messenger is generated by the activity of a range of adenylyl cyclase isoforms following hormone or neurotransmitter-mediated activation of their coupled heterotrimeric G-protein, G<sub>sa</sub>. Its subsequent hydrolysis to 5'AMP is brought about by one or more of a range of cAMP phosphodiesterases (PDEs)<sup>1</sup>. The resulting intracellular cAMP concentration, [cAMP]<sub>i</sub>, influences a wide range of physiologically important cellular signalling processes. The exact processes affected and the nature of their regulation varies with the particular specialisation of the cells concerned. Osteoclasts exemplify a terminally differentiated, highly specialised cell type which degrade mineralized matrix during normal and pathological bone turnover. Following the proliferation and migration of hemopoietic osteoclast progenitors to bone and their differentiation and fusion to form these multinucleated cells, osteoclast function involves their migration to and between resorption sites, prior to highly specialised and closely regulated resorption episodes terminated by cell retraction and regulated both by local extracellular Ca<sup>2+</sup> and systemic calcitonin action<sup>2</sup>.

### ***Components of osteoclast motility and retraction properties following calcitonin action: the 'Q' and 'R' effects***

Long-range regulation of osteoclast activity involves calcitonin action, for which [cAMP]<sub>i</sub> complements intracellular Ca<sup>2+</sup> concentration, [Ca<sup>2+</sup>]<sub>i</sub> as a cellular second messenger<sup>3,4</sup>. These two messenger systems exert distinct physiological effects consistent with their representing distinct activation pathways. Nevertheless both culminate in inhibition of bone resorptive activity. Calcitonin increased cAMP levels in both bone<sup>5</sup> and isolated osteoclasts<sup>6</sup>. In isolated rat osteoclasts, the lowest effective calcitonin concentrations replicated the effects of agents known directly to elevate [Ca<sup>2+</sup>]<sub>i</sub> including elevated extracellular [Ca<sup>2+</sup>], and perchlorate and ionomycin challenge<sup>7</sup>. They induce retraction ('R' effect) of cell spread area and inhibit bone resorptive activity over 2-3 h following stimulus application whilst sparing cellular motility in the form of cell retraction and protrusion activity. These effects accompanied transient elevations in [Ca<sup>2+</sup>]<sub>i</sub><sup>8</sup>. These effects were not replicated by calcitonin analogues such as amylin or calcitonin gene-related peptide (CGRP), yet the latter are similarly known to reduce bone resorption<sup>9</sup>.

However, higher calcitonin concentrations additionally induced a quiescence ('Q' effect) in osteoclast motility, reflected in a cessation of cell retraction and protrusion activity that was distinct from the R effect<sup>10</sup>. It also reduced the margin ruffling implicated in resorptive hemivacuole formation and bone resorptive activity and increased secretion of the osteoclast-specific enzyme tartrate-resistant acid phosphatase (TRAP). The Q effect could be selectively replicated in an absence of the R effect by the calcitonin analogues amylin, β-CGRP<sup>9</sup>, or the peptide CGRP fragment CGRP-(Val<sup>8</sup>Phe<sup>37</sup>), findings also

1  
2 accompanied by reduced bone resorption<sup>9,11</sup>. However, in contrast to agents associated with the R effect,  
3 none of these latter manoeuvres elevated osteoclast  $[Ca^{2+}]_i$ <sup>9</sup>. The Q effect was associated with reductions in  
4 supernatant TRAP and reduced osteoclast-mediated bone resorption in vitro.  
5  
6

7  
8 These Q and R effects could be separated firstly by the application of terms quantifying a parameter,  $\rho$ ,  
9 describing cell spread area changes resulting from cell retraction ('R') and a motility parameter  $\mu$  summing  
10 retraction ( $\Delta r$ )-protrusion ( $\Delta p$ ) activity during the Q effect in isolated osteoclasts (Fig. 1A)<sup>10</sup>. These  
11 demonstrated that calcitonin produced time-dependent reductions in both  $\rho$  and  $\mu$  terms (Fig. 1B). In  
12 contrast, extracellular  $Ca^{2+}$  challenge selectively altered the  $\rho$  term with relatively little change in  $\mu$  (Fig.  
13 1C). Conversely, amylin challenge selectively altered the  $\mu$  parameter whilst leaving  $\rho$  relatively unchanged  
14 (Fig. 1D). Secondly, use of CGRP-(Val<sup>8</sup>Phe<sup>37</sup>) as a calcitonin antagonist, abolished the calcitonin-induced Q  
15 but not the R effect of calcitonin. Thus, the Q and R effects of calcitonin action may reflect activation of  
16 pharmacologically distinct receptor targets and signalling pathways<sup>12</sup>.  
17  
18  
19  
20  
21  
22  
23

### 24 ***G-protein involvement in the Q and R effects: involvement of cAMP signalling***

25  
26 Different G-protein agonists recapitulated the Q or R effects either in isolation or in combination<sup>4</sup>. The  
27 universal G-protein agonist tetrafluoro-aluminate ( $AlF_4^-$ ) produced both Q and R effects together<sup>4</sup>. This was  
28 accompanied by a concentration-dependent inhibition of bone resorption, yet a paradoxically increased in  
29 TRAP enzyme secretion<sup>13</sup>. Pertussis toxin has been previously implicated in  $G_{i/o}$  protein inhibition. In  
30 osteoclasts, it selectively induced an R effect, in the absence of an Q effect, suggestive of a novel  $Ca^{2+}$   
31 dependent G-protein mediated mechanism. Thus, as also reported in connection with platelet aggregation  
32 and activation<sup>14</sup>, as well as a number of other cell types<sup>15</sup>, pertussis toxin may exert effects that increase  
33 osteoclastic  $[Ca^{2+}]_i$  independent of its previously established ADP-ribosylation action on  $G_{i/o}$ . These findings  
34 were accompanied by reduced bone resorption though a relatively limited reduction in enzyme release. In  
35 contrast, the Q effect was replicated selectively, in the absence of an R effect, with challenge by the  $G_s$   
36 protein stimulator cholera toxin<sup>13,16</sup>. This was similarly accompanied by a reduction in bone resorption but  
37 an enhanced TRAP secretion. The latter effects likely were mediated by an increase of  $[cAMP]_i$  previously  
38 attributed to cholera toxin induced  $G_s$  protein activation. Thus, they were mimicked by the adenylate cyclase  
39 activator forskolin<sup>16</sup> and dibutyryl cyclic AMP<sup>17,18</sup>, and potentiated by the phosphodiesterase inhibitor  
40 theophylline<sup>17</sup>.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 ***Protein kinase A vs. Epac mediated pathways involving cAMP***

52 The  $[cAMP]_i$ -mediated actions *inhibiting* cellular function in the bone-resorbing osteoclast following  
53 calcitonin action complement their classically described *activating* effects in cardiomyocytes. The latter  
54 follow  $\beta_1$  adrenergic stimulation which results in a cAMP-induced activation of protein kinase A (PKA)  
55 mediated phosphorylation activity of a wide range of regulatory molecules involved in cellular  $Ca^{2+}$   
56  
57  
58  
59

1  
2 signalling. Thus, PKA-mediated L-type  $\text{Ca}^{2+}$  channel phosphorylation enhances inward voltage-dependent  
3 L-type  $\text{Ca}^{2+}$  current and extracellular  $\text{Ca}^{2+}$  entry resulting from such channel opening during action potential  
4 excitation. The consequent sarcoplasmic reticular (SR) ryanodine receptor (RyR2)- $\text{Ca}^{2+}$  channel mediated  
5  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release is further increased with RyR2 phosphorylation. These phosphorylation events  
6 thus markedly accentuate the elevations in systolic cytosolic  $[\text{Ca}^{2+}]$  resulting from excitation-contraction  
7 coupling. Conversely, PKA-mediated phosphorylation of the inhibitory peptide phospholamban increases  
8 the SR  $\text{Ca}^{2+}$ -ATPase mediated uptake of  $\text{Ca}^{2+}$  from cytoplasm to SR that reduces cytosolic  $[\text{Ca}^{2+}]$  to its  
9 background level during cardiomyocyte relaxation<sup>19</sup>.

10  
11 However, cAMP also exerts PKA-independent effects. In sino-atrial node cells, cAMP binding to  
12 hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels mediating pacemaker ( $I_f$ ) ionic currents  
13 increases heart rate<sup>20</sup>. Furthermore, there has been much recent interest about the role of exchange proteins  
14 directly activated by cAMP (Epac)<sup>21-24</sup>. In cardiomyocytes, Epac signaling offers an alternative or co-  
15 existent cAMP-dependent regulatory mechanism that operates downstream of  $\beta$  adrenergic receptor  
16 activation but upstream of the RyR2-mediated  $\text{Ca}^{2+}$ -induced SR  $\text{Ca}^{2+}$  release underlying excitation-  
17 contraction coupling<sup>25,26</sup>. Thus, the cAMP analog 8-(4-chlorophenylthio)-2'-O-methyladenosine 3', 5'-  
18 cyclic monophosphate (8-CPT) when applied at concentrations preferentially activating Epac rather than  
19 PKA<sup>27</sup> elicited spontaneous, or increased amplitudes of electrically evoked, cytosolic  $\text{Ca}^{2+}$  transients, as well  
20 as spontaneous propagated cytosolic  $\text{Ca}^{2+}$  waves, in rat or mouse cardiac myocytes<sup>23</sup>. Such phenomena  
21 potentially increase electrogenic  $\text{Na}^+/\text{Ca}^{2+}$  exchange current activity accounting for the pro-arrhythmic  
22 triggering electrophysiological activity that was observed accompanying such alterations in  $\text{Ca}^{2+}$   
23 homeostasis<sup>23,28-32</sup>. These effects also followed isoproterenol-mediated adrenergic agonist activation in the  
24 presence of the PKA inhibitor H-89<sup>33</sup>. They thus appear to reflect a cAMP-mediated, PKA-independent  
25 regulatory mechanism, specifically acting on excitation-contraction coupling through modulation of RyR2  
26 activation<sup>23</sup>. Thus they were abolished with genetic ablation of Epac2,  $\beta_1$  adrenoreceptor,  $\text{Ca}^{2+}$ /calmodulin-  
27 dependent protein kinase II- $\delta$  (CaMKII $\delta$ ) and RyR2-S2814 phosphorylation<sup>34</sup>. Furthermore, murine *Epac1*<sup>-/-</sup>,  
28 *Epac2*<sup>-/-</sup> and *CaMKII $\delta$* <sup>-/-</sup> hearts showed normal indices for other cardiac functions. These included in vivo  
29 cardiac structure, ratios of heart to body weight, cardiac contractility or pressure overload-induced  
30 hypertrophy, and their responses to adrenergic dobutamine challenge, and cellular SR  $\text{Ca}^{2+}$ -ATPase and  
31  $\text{Na}^+/\text{Ca}^{2+}$  exchanger protein expression levels, and  $\text{Ca}^{2+}$  content<sup>34</sup>.

32  
33 Since their discovery, Epac proteins have been implicated in a wide range of critical physiological actions of  
34 cAMP<sup>35</sup>. The present article speculates on a possible role for this system in osteoclast function in the context  
35 of available evidence. Epac exists in three isoforms. Of these, Epac1, Epac2 and Repac all include a Ras-  
36 association domain (RA)<sup>36</sup> (Fig. 2). Epac1 and Epac2 are membrane bound proteins reflecting their  
37 possession of a dishevelled-Egl-10-pleckstrin (DEP) domain. Epac1 contains a regulatory, cyclic  
38 <http://www.nyas.org/forthcoming>

mononucleotide-binding (CNB) domain with a natively disordered, N-terminal extension<sup>37</sup> permitting activation by direct cAMP binding<sup>38,39</sup>. Epac2 contains an additional lower affinity amino-terminal cAMP-binding (CNB) site<sup>37,40</sup>. This is N-terminal to the DEP domain and has a 20-fold lower cAMP affinity than the conserved CNB. These regulatory domains are joined via a Ras exchange motif (REM) and an intervening RA domain to the cell division cycle phosphatase-25 (Cdc25) homology domain (CDC25HD) responsible for guanine nucleotide-exchange activity. The isoform related to Epac, Repac, only includes a catalytic region, consistent with it being constitutively active or having a separate regulatory site<sup>37,41</sup>. Of the isoforms directly regulated by cAMP, cellular expression of Epac1 appears ubiquitous, whereas Epac2 occurs preferentially in brain, pituitary, and adrenal gland. In contrast to Epac1 and to the apparent  $[Ca^{2+}]_i$ -independence of the osteoclastic Q effect, Epac2 has been associated with regulation of processes dependent upon  $Ca^{2+}$  signaling<sup>25,42</sup>. Thus, besides producing growth arrest in neuroendocrine cells, Epac2 located at cardiomyocyte transverse tubules may regulate potentially arrhythmogenic SR  $Ca^{2+}$  leak and/or  $Ca^{2+}$  induced  $Ca^{2+}$  release through SR RyR2- $Ca^{2+}$  release channels<sup>23,43</sup>. Epac2 has also been implicated in endoplasmic reticular  $Ca^{2+}$  dependent secretory events in pancreatic cells<sup>44-48</sup>. It has been suggested that in these situations it acts through activation of a novel phosphoinositide (PI) phospholipase C isoform (PLC $\epsilon$ ), protein kinase C (PKC), and CaMKII<sup>35</sup>. Epacs can also function as guanine nucleotide-exchange factors (GEFs) facilitating exchange of GDP for GTP binding in small guanine nucleotide-binding (G) proteins. In general, GEFs activate signalling by catalyzing the exchange from G-protein-bound GDP to GTP. In contrast, GTPase-activating proteins (GAPs) terminate such signalling by inducing GTP hydrolysis. GEFs promote the GTP-bound, active, form. GAPs promote the GDP-bound, inactive, form (Fig. 3). Both GEFs and GAPs contain multiple domains mediating regulation by both extracellular signals and localized events<sup>49</sup>.

### ***Rap1 as a target for Epac-mediated regulation***

Amongst the small guanine nucleotide-binding (G) proteins that cycle between GDP- and GTP-bound forms, Ras proteins, resident at the cytoplasmic surface of cell membranes, are of particular importance. They act as cellular switches in signal transduction<sup>50</sup>. The Ras-proximate or Ras-related proteins (Rap) constitute one group within the Ras protein superfamily<sup>39</sup>. These contain a C-terminal tetrapeptide sequence motif Cys-Ali-Ali-X, where Ali is an aliphatic amino acid and X is any amino acid. This constitutes the site of membrane attachment via isoprenylation for ras, nuclear lamins and  $\gamma$ -subunits of the heterotrimeric G-proteins. Rap1 is thus localized to the cytosolic side of internal membranes such as endosomes and secretory granules compatible with roles in recruiting components for vesicle formation and/or transport.

In contrast to Ras, in which mutations are associated with cell proliferation and human neoplasms, genetic studies suggest that of Rap proteins, Rap1 is primarily involved in cell adhesion and cell junction formation<sup>51</sup>. Rap1 proteins, exist as two similar isoforms in many animal tissues, Rap1a and Rap1b,

1  
2 differing by only a few amino acids<sup>42,51</sup>. Rap2a (previously Rap2) proteins are found mostly in platelets and  
3 brain tissue. They have been less extensively studied than Rap1, but have been implicated in Epac2-  
4 dependent growth arrest in neuroendocrine cells, and Ca<sup>2+</sup>-dependent secretory events in pancreatic cells<sup>44,45</sup>.  
5 Rap2b has been reported in *Escherichia coli* systems.  
6  
7  
8  
9

10 Ras and Rap are regulated by different GEFs and GAPs<sup>52</sup>. Epac is likely one of a range of these GEFs  
11 regulating the Rap1 member of this family (Fig. 3). Thus, in addition to transmembrane receptors such as  
12 receptor tyrosine kinases, heterotrimeric G-protein-coupled receptors, cytokine receptors and cell-adhesion  
13 molecules<sup>53</sup>, common second messengers such as cAMP, Ca<sup>2+</sup> and diacylglycerol appear involved in  
14 transducing extracellular signals to Rap1<sup>54</sup>. Rap1 can also be activated by PKA-mediated phosphorylation  
15 but the functional significance of this is unclear but may even concern Rap1 inactivation<sup>55</sup>, activation of  
16 other messengers such as B-raf<sup>56</sup>, and involve an indirect, Ca<sup>2+</sup>-dependent pathway<sup>57</sup>.  
17  
18  
19  
20  
21  
22

23 Rap1 has been implicated in a range of processes dependent on integrin-dependent activation, exemplified in  
24 its requirement for phagocytosis by mouse macrophages and by *Dictyostelium discoideum*. It is also  
25 implicated in other processes that might involve integrin-mediated cell adhesion, morphogenesis,  
26 haematopoiesis, leukocyte migration and tumour invasion. It has been suggested that Rap1 activates  
27 integrins by stimulating cell surface receptors through currently uncertain mechanisms<sup>58-61</sup>. Rap1 has also  
28 been implicated in the recruitment to and activation of Phg2 at the leading edge of chemotaxin *D.*  
29 *discoideum* cells required for myosin II phosphorylation and disassembly in pseudopodial formation<sup>62</sup>.  
30  
31  
32  
33  
34  
35

### 36 ***Epac modification alters osteoclast development and function***

37  
38 The selective Epac activator, 8-CPT, enhanced, whilst the Epac inhibitor brefeldin A reduced the osteoclast  
39 differentiation that followed stimulation by receptor activator of nuclear factor  $\kappa$ -B ligand (RANKL)<sup>63</sup> in  
40 primary murine and human bone marrow culture studies. Such differentiation accompanied cellular  
41 morphological alterations from centrally-sited nuclei surrounded by a ring of F-actin and absence of  
42 podosomes to large multinucleate osteoclasts with a peripheral podosome belt, showing TRAP production.  
43  
44  
45  
46

47  
48 Similar findings were made in RAW264.7 cells in which these findings were further confirmed by the  
49 additional, recently available, Epac activation inhibitors 4-methylphenyl-2,4,6-trimethylphenylsulfone (ESI-  
50 05) and 3-[5-(*tert*-butyl)isoxazol-3-yl]-2-[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile (ESI-09).  
51 Silencing either Epac1 or Epac2 by shRNA prevented this differentiation in the RAW264.7 cells. These  
52 findings were reflected in mRNA levels of the differentiation markers cathepsin K, nuclear factor of  
53 activated T cells c1 (NFATc1) and osteopontin, and reduced numbers of formed resorption pits in dentine  
54 slides. The findings paralleled reductions in RANKL-induced Rap1 activation, and in reduced activation of  
55 proteins that were involved in actin cytoskeletal changes. The latter included reductions in the Ras homolog  
56  
57  
58  
59  
60



1  
2 RhoA, involved in stress fibre formation, cell cycle regulation and cell development, and Ras-related C3  
3 botulinum toxin substrate 1 (Rac1), involved in lamellipod formation and cell-cell adhesion, with Epac1 or  
4 Epac2 suppression. They included reductions in cdc42, involved in filopodial assembly, with Epac1, but not  
5 Epac2, suppression and reductions in focal adhesion kinase (FAK), involved in cellular adhesion, with  
6 Epac2, but not Epac1, suppression<sup>64,65</sup>. Direct activation of Rac1 and FAK is necessary for actin  
7 cytoskeleton rearrangements during osteoclast differentiation. Finally, Epac1 or Epac2 silencing reduced the  
8 RANKL-induced cytoplasm to nuclear translocation of p50/p105 nuclear factor  $\kappa$ -light-chain-enhancer of  
9 activated B cells (NF $\kappa$ B) associated with normal osteoclast differentiation<sup>66</sup>.

### 16 ***Integrins are potential effectors for Rap1 in regulating osteoclast motility and bone*** 17 ***resorption***

18  
19 Integrins form a family of heterodimeric adhesion receptors involved in cell–matrix and cell–cell  
20 interactions central to a wide variety of cell functions, including leukocyte homing and activation, cell  
21 responses to mechanical stress, apoptosis, and tumour growth and metastases<sup>67</sup>. Osteoclast motile and  
22 secretory activity similarly involve integrin-dependent, cell–matrix and cell–cell interactions<sup>68</sup>. Osteoclast  
23 activity involves cell migration, adhesion to bone surfaces, and formation of a tight clear sealing zone that  
24 encloses a resorption lacuna. After insertion of secretory vesicles, a ruffled border comprising a highly  
25 convoluted membrane facing the bone surface is formed.

26  
27 Mammalian osteoclasts express the  $\alpha_v\beta_3$  integrin/vitronectin receptor, at high levels, as well as the  
28 collagen/laminin receptor  $\alpha_2\beta_1$  and the vitronectin/fibronectin receptor  $\alpha_v\beta_1$ <sup>69</sup>. The  $\alpha$  and  $\beta$  integrin  
29 cytoplasmic domains do not themselves have enzymatic activities. However, integrins interact with a range  
30 of matrix, and cytoskeletal and signaling molecules (Fig. 4). First, integrins mediate osteoclast adhesion to  
31 the bone surface by interacting with extracellular matrix proteins within the bone matrix. Rat osteoclasts  
32 adhere in an  $\alpha_v\beta_3$ -dependent manner to matrix proteins containing RGD (Arg-Gly-Asp) sequences, including  
33 vitronectin, osteopontin, bone sialoprotein and a cryptic RGD-site in denatured collagen type I, and in a  
34  $\alpha_2\beta_1$ - and RGD-dependent manner to collagen type I<sup>70,71</sup>. Correspondingly, antibodies raised to  $\alpha_2$ ,  $\beta_1$  and  
35  $\alpha_v\beta_3$  inhibit bone resorption<sup>72,73</sup>. Second, integrin-ligand binding induces receptor clustering causing  
36 formation of focal adhesion contacts, recruitment of and linkage to cytoskeletal molecules including  
37 paxillin, vinculin, gelsolin and F-actin with an organisation of intracellular cytoskeletal complexes,  
38 additionally leading to changes in cell shape, spreading and motility<sup>74,75</sup>. Thirdly, integrins mediate  
39 transmembrane transduction of signals in both inside-out and outside-in directions relating organization of  
40 the actin network and the composition of the focal adhesions, through the cytoskeletal protein talin which  
41 links integrins to the actin cytoskeleton, and is an essential mediator of integrin activation<sup>76</sup>. Fourthly, a  
42 wide range of signaling pathways including those involving phosphatidylinositol 3-kinase, c-Src, protein  
43 tyrosine kinase 2  $\beta$  (PYK2) and p130<sup>cas</sup> are  $\alpha_v\beta_3$  integrin-dependent<sup>77,78</sup>.

### ***Rap1 and its interaction with integrins are essential to osteoclast bone resorptive activity***

Studies in genetically modified murine models suggest that both Talin and Rap1 are critical for osteoclastic bone resorptive activity in vivo<sup>79</sup>. Talin1-deficient osteoclast precursors showed normal osteoclast differentiation markers following exposure to macrophage colony-stimulating factor (M-CSF) and RANKL. However, they showed compromised attachment to and migration over bone substrate. The talin-deficient mice correspondingly showed osteopetrotic phenotypes. Mice with a talin deletion made late in the course of osteoclastogenesis showed a reduction in both ovariectomy-induced osteoporosis and periarticular osteolysis associated with inflammatory arthritis. Osteoclast-specific deletion of Rap1 (CtsK-Rap1), which promotes talin/ $\beta$ -integrin recognition, also yielded mice with an osteopetrotic phenotype. In both these examples, this was more severe, with up to fivefold increases in bone mass, than the phenotype associated with  $\alpha_v\beta_3$ -deficiency, likely due to the additional added failed activation of  $\beta_1$  integrins.

### ***Translational implications of Epac and Rap1 signalling: relationships to bisphosphonate action***

A possible translational outcome of testing a hypothesis implicating involvements of Epac regulation of Rap1 activity in osteoclast function may include targeted therapeutic intervention with reduced side effects, directed at bone diseases. Of these, osteoporosis is a widespread, often initially asymptomatic, insidious, disease of progressive bone loss and skeletal deterioration increasing fragility and liability to bone fracture. Its manifestations become commoner with age, particularly in postmenopausal women, affecting <1 in 2 women and <1 in 5 men over age 50 y. Bisphosphonates provide effective therapy: postmenopausal women receiving alendronate for 10 years showed fewer clinical vertebral fractures than those altered to placebo at 5 years in the Fracture Intervention Trial Long-term Extension (FLEX)<sup>80</sup>. Similarly, women who received 6 annual infusions of zoledronic acid showed fewer vertebral fractures than those altered to placebo after 3 years in the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON) extension<sup>81</sup>. **Experimental studies report that relatively high (~10  $\mu$ M) concentrations of nitrogen-containing bisphosphonates prevent post-translational prenylation of small GTPases not only in Rac, Rho, Cdc42, and Rab but also in Rap1 proteins, not only in J774 macrophages but also osteoclasts in vitro and in vivo<sup>82,83</sup>. This effect was attributed to inhibition of cholesterol biosynthetic pathways generating farnesyl pyrophosphate and geranyl diphosphate<sup>84</sup> substrates for post-translational protein prenylation. Prenylation of small GTPases enables their localization to the correct subcellular membranes and interaction with regulatory proteins<sup>85</sup>. Conversely, inhibition of such protein geranylgeranylation by nitrogen containing bisphosphonates resulted in cytoskeletal disruption, reduced resorptive activity and osteoclast apoptosis<sup>86,87</sup>. **Although the concentrations at which these effects occurred are unlikely to be reached in clinical practice, these findings broadly draw attention to Rap1 prenylation as a potential therapeutic target amenable to upstream approaches to therapy through the Epac-Rap signalling****

1  
2 system. This could lead to alternative treatment strategies potentially avoiding some side effects of  
3 conventional bisphosphonate therapy<sup>88,89</sup>.  
4  
5

### 6 7 **Summary of abbreviations.**

8  
9  $\Delta p$ , cell protrusion increment;  $\Delta r$ , cell retraction increment; 5'AMP, 5' adenosine monophosphate; 8-CPT, 8-(4-  
10 chlorophenylthio)-2'-O-methyladenosine 3', 5'-cyclic monophosphate;  $A$ , cell spread area; CaMKII,  
11  $\text{Ca}^{2+}$ /calmodulin-dependent protein kinase II; cAMP, 3'-5'-cyclic adenosine monophosphate; Cdc25, cell division  
12 cycle phosphatase-25; CDC25HD, Cdc25 homology domain; CGRP, calcitonin gene-related peptide; CNB, cyclic  
13 mononucleotide-binding domain; DEP, dishevelled-Egl-10-pleckstrin domain; Epac, exchange protein directly  
14 activated by cAMP; ESI-05, 4-methylphenyl-2,4,6-trimethylphenylsulfone; ESI-09, 3-[5-(*tert*-butyl)isoxazol-3-yl]-2-  
15 [2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile; FAK, focal adhesion kinase; FLEX, Fracture Intervention Trial  
16 Long-term Extension; GAP, GTPase-activating protein; GDP, guanine diphosphate; GEF, guanine nucleotide-  
17 exchange factor; GTP, guanine triphosphate;  $G_x$ , guanine nucleotide-binding protein [ $x = s$ , stimulatory,  $i$ , inhibitory,  
18  $o$ , other]; HCN, hyperpolarisation-activated cyclic nucleotide-gated; HORIZON, Health Outcomes and Reduced  
19 Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial;  $I_f$ , sino-atrial node pacemaker current; M-CSF,  
20 macrophage colony-stimulating factor;  $\mu$ , cell motility parameter; NFATc1, nuclear factor of activated T-cells,  
21 cytoplasmic 1; NF $\kappa$ B, nuclear factor  $\kappa$ -light-chain-enhancer of activated B cells; PDE, phosphodiesterase; PI,  
22 phosphoinositide; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PYK2, Protein  
23 tyrosine kinase 2 $\beta$ ; Q, cell quiescence; R, cell retraction; Rac1, Ras-related C3 botulinum toxin substrate 1;  
24 RANK, nuclear factor  $\kappa$ -B; RANKL, nuclear factor  $\kappa$ -B ligand; Rap, Ras-proximate or Ras-related protein; Ras, rat  
25 sarcoma; RA, Ras association domain; REM, Ras exchange motif; Repac, related to Epac;  $\rho$ , cell retraction parameter;  
26 RGD, Arg-Gly-Asp; RhoA, Ras homolog A; RyR2, ryanodine receptor type 2; SR, sarcoplasmic reticulum;  $t$ , time;  
27 TRAP, tartrate-resistant acid phosphatase.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Acknowledgements**

40  
41 The authors' work is funded by the Medical Research Council, British Heart Foundation (BHF) and  
42 Cambridge BHF Centre for research excellence.  
43  
44  
45

### 46 **Conflicts of interest.**

47  
48 None declared.  
49  
50  
51  
52

### 53 **References**

- 54  
55 1. Houslay M.D. 1998. Adaptation in cyclic AMP signalling processes: A central role for cyclic AMP  
56 phosphodiesterases. *Semin. Cell Dev. Biol.* **9**: 161–167.  
57  
58  
59  
60

2. Zaidi M., A.S.M.T. Alam, V.S. Shankar, *et al.* 1993. Cellular biology of bone resorption. *Biol. Rev. Camb. Philos. Soc.* **68**.
3. Zaidi M., M. Pazianas, V. Shankar, *et al.* 1993. Osteoclast function and its control. *Exp. Physiol.* **78**: 721–739.
4. Zaidi M., H.K. Datta, B.S. Moonga, *et al.* 1990. Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways. *J. Endocrinol.* **126**: 473–481.
5. Zaidi M., L.H. Breimer & I. MacIntyre. 1987. Biology of peptides from the calcitonin genes. *Q. J. Exp. Physiol.* **72**: 371–408.
6. Nicholson G.C., J.M. Moseley, P.M. Sexton, *et al.* 1986. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. *J. Clin. Invest.* **78**: 355–360.
7. Zaidi M., B.S. Moonga & C.L.H. Huang. 2004. Calcium sensing and cell signaling processes in the local regulation of osteoclastic bone resorption. *Biol. Rev. Camb. Philos. Soc.* **79**: 79–100.
8. Moonga B.S., A.S.M. Towhidul Alam, P.J.R. Bevis, *et al.* 1992. Regulation of cytosolic free calcium in isolated rat osteoclasts by calcitonin. *J. Endocrinol.* **132**: 241–249.
9. Alam A., B. Moonga, P. Bevis, *et al.* 1993. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. *Exp. Physiol.* **78**: 183–196.
10. Zaidi M., A.S.M.T. Alam, V.S. Shankar, *et al.* 1992. A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function. *Eur. Biophys. J.* **21**: 349–355.
11. Zaidi M., K. Fuller, P.J. Bevis, *et al.* 1987. Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study. *Calcif. Tissue Int.* **40**: 149–54.
12. Alam A.S.M., B.S. Moonga, P.J.R. Bevis, *et al.* 1991. Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide-(Val8Phe37). *Biochem. Biophys. Res. Commun.* **179**.
13. Moonga B.S., M. Pazianas, A.S.M.T. Alam, *et al.* 1993. Stimulation of a Gs-like G protein in the osteoclast inhibits bone resorption but enhances tartrate-resistant acid phosphatase secretion. *Biochem. Biophys. Res. Commun.* **190**.
14. Sindt K.A., E.L. Hewlett, G.T. Redpath, *et al.* 1994. Pertussis toxin activates platelets through an interaction with platelet glycoprotein Ib. *Infect. Immun.* **62**: 3108–3114.
15. Wong W.S. & P.M. Rosoff. 1996. Pharmacology of pertussis toxin B-oligomer. *Can J Physiol Pharmacol* **74**: 559–564.
16. Alam A.S.M.T., C.M.R. Bax, V.S. Shankar, *et al.* 1993. Further studies on the mode of action of calcitonin on isolated rat osteoclasts: Pharmacological evidence for a second site mediating intracellular Ca<sup>2+</sup>-mobilization and cell retraction. *J. Endocrinol.* **136**: 7–15.
17. Chambers T.J. & N.N. Ali. 1983. Inhibition of osteoclastic motility by prostaglandins I<sub>2</sub>, E<sub>1</sub>, E<sub>2</sub> and 6-oxo-E<sub>1</sub>. *J. Pathol.* **139**: 383–397.
18. Zaidi M. 1990. Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function. *Biosci. Rep.* **10**: 547–556.
19. Bers D.M. 2008. Calcium cycling and signaling in cardiac myocytes. *Annu. Rev. Physiol.* **70**: 23–49.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Berthouze M., A.C. Laurent, M. Breckler, *et al.* 2011. New perspectives in cAMP-signaling modulation. *Curr. Heart Fail. Rep.* **8**: 159–167.
21. El-Armouche A. & T. Eschenhagen. 2009.  $\beta$ -Adrenergic stimulation and myocardial function in the failing heart. *Heart Fail. Rev.* **14**: 225–241.
22. Li M., S.S. Hothi, S.C. Salvage, *et al.* 2017. Arrhythmic effects of Epac-mediated ryanodine receptor activation in Langendorff-perfused murine hearts are associated with reduced conduction velocity. *Clin. Exp. Pharmacol. Physiol.* **44**: 686–692.
23. Hothi S.S., I.S. Gurung, J.C. Heathcote, *et al.* 2008. Epac activation, altered calcium homeostasis and ventricular arrhythmogenesis in the murine heart. *Pflugers Arch.* **457**: 253–70.
24. Valli H., S. Ahmad, S. Sriharan, *et al.* 2017. Epac-induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes. *Clin Exp Pharmacol Physiol* doi: **10.11**.
25. De Rooij J., F.J. Zwartkruis, M.H. Verheijen, *et al.* 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* **396**: 474–477.
26. Kawasaki H., G.M. Springett, N. Mochizuki, *et al.* 1998. A family of cAMP-binding proteins that directly activate Rap1. *Science* **282**: 2275–2279.
27. Holz G.G., G. Kang, M. Harbeck, *et al.* 2006. Cell physiology of cAMP sensor Epac. *J. Physiol.* **577**: 5–15.
28. Morel E., A. Marcantoni, M. Gastineau, *et al.* 2005. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. *Circ. Res.* **97**: 1296–1304.
29. Oestreich E.A., H.A. Wang, S. Malik, *et al.* 2007. Epac-mediated activation of phospholipase C epsilon plays a critical role in beta-adrenergic receptor-dependent enhancement of Ca<sup>2+</sup> mobilization in cardiac myocytes. *J. Biol. Chem.* **282**: 5488–5495.
30. Pereira L., M. Métrich, M. Fernández-Velasco, *et al.* 2007. The cAMP binding protein Epac modulates Ca<sup>2+</sup> sparks by a Ca<sup>2+</sup>/calmodulin kinase signalling pathway in rat cardiac myocytes. *J. Physiol.* **583**: 685–94.
31. Berlin J.R., M.B. Cannell & W.J. Lederer. 1989. Cellular origins of the transient inward current in cardiac myocytes. Role of fluctuations and waves of elevated intracellular calcium. *Circ. Res.* **65**: 115–126.
32. Pogwizd S.M. & D.M. Bers. 2004. Cellular basis of triggered arrhythmias in heart failure. *Trends Cardiovasc. Med.* **14**: 61–66.
33. Murray A.J. 2008. Pharmacological PKA inhibition: all may not be what it seems. *Sci. Signal.* **1**: re4.
34. Pereira L., H. Cheng, D.H. Lao, *et al.* 2013. Epac2 mediates cardiac  $\beta$ 1-adrenergic-dependent sarcoplasmic reticulum Ca<sup>2+</sup> leak and arrhythmia. *Circulation* **127**: 913–922.
35. Almahariq M., F.C. Mei & X. Cheng. 2014. Cyclic AMP sensor EPAC proteins and energy homeostasis. *Trends Endocrinol. Metab.* **25**: 60–71.
36. Rebhun J.F., A.F. Castro & L.A. Quilliam. 2000. Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase. *J. Biol. Chem.* **275**: 34901–34908.
37. De Rooij J., H. Rehmann, M. Van Triest, *et al.* 2000. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. *J. Biol. Chem.* **275**: 20829–20836.
38. De Rooij J., F.J.T. Zwartkruis, M.H.G. Verheijen, *et al.* 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* **396**: 474–477.

- 1
- 2 39. Kawasaki H., G.M. Springett, N. Mochizuki, *et al.* 1998. A family of cAMP-binding proteins that directly
- 3 activate Rap1. *Science (80-. )*. **282**: 2275–2279.
- 4
- 5 40. Ozaki N., T. Shibasaki, Y. Kashima, *et al.* 2000. cAMP-GEFII is a direct target of cAMP in regulated
- 6 exocytosis. *Nat. Cell Biol.* **2**: 805–811.
- 7
- 8 41. Ichiba T., Y. Hoshi, Y. Eto, *et al.* 1999. Characterization of GFR, a novel guanine nucleotide exchange factor
- 9 for Rap1. *FEBS Lett.* **457**: 85–9.
- 10
- 11 42. Bos J.L. 2003. Epac: a new cAMP target and new avenues in cAMP research. *Nat. Rev. cell Biol.* **4**: 733–738.
- 12
- 13 43. Pereira L., H. Rehmann, D.H. Lao, *et al.* 2015. Novel Epac fluorescent ligand reveals distinct Epac1 vs. Epac2
- 14 distribution and function in cardiomyocytes. *Proc Natl Acad Sci U S A* **112**: 3991–3996.
- 15
- 16 44. Emery A.C., W. Xu, M. V. Eiden, *et al.* 2017. Guanine nucleotide exchange factor Epac2–dependent activation
- 17 of the GTP-binding protein Rap2A mediates cAMP-dependent growth arrest in neuroendocrine cells. *J. Biol.*
- 18 *Chem.* **292**: 12220–12231.
- 19
- 20 45. Kang G., O.G. Chepurny & G.G. Holz. 2001. cAMP-regulated guanine nucleotide exchange factor II (Epac2)
- 21 mediates Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release in INS-1 pancreatic  $\beta$ -cells. *J. Physiol.* **536**: 375–385.
- 22
- 23 46. Dzhura I., O.G. Chepurny, G.G. Kelley, *et al.* 2010. Epac2-dependent mobilization of intracellular Ca<sup>2+</sup> by
- 24 glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in  $\beta$ -cells of phospholipase C- $\epsilon$  knockout mice.
- 25 *J. Physiol.* **588**: 4871–4889.
- 26
- 27 47. Kim B.-J., K.-H. Park, C.-Y. Yim, *et al.* 2008. Generation of nicotinic acid adenine dinucleotide phosphate and
- 28 cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca<sup>2+</sup> signal that is essential for insulin secretion in mouse
- 29 pancreatic islets. *Diabetes* **57**:
- 30
- 31 48. Dzhura I., O.G. Chepurny, C.A. Leech, *et al.* 2011. Phospholipase C- $\epsilon$  links Epac2 activation to the
- 32 potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. *Islets* **3**: 121–128.
- 33
- 34 49. Bos J., H. Rehmann & A. Wittinghofer. 2007. GEFs and GAPs : Critical Elements in the Control of Small G
- 35 Proteins. *Cell* 865–877.
- 36
- 37 50. Burbach B.J., R.B. Medeiros, K.L. Mueller, *et al.* 2007. T-cell receptor signaling to integrins. *Immunol. Rev.*
- 38 **218**: 65–81.
- 39
- 40 51. Bos J.L., J. De Rooij & K.A. Reedquist. 2001. Rap1 signalling: Adhering to new models. *Nat. Rev. Mol. Cell*
- 41 *Biol.* **2**: 369–377.
- 42
- 43 52. Raaijmakers J.H. & J.L. Bos. 2010. Specificity in Ras and Rap Signalling. *J. Biol. Chem.* **284**: 10995–10999.
- 44
- 45 53. McLeod S.J., R.J. Ingham, J.L. Bos, *et al.* 1998. Activation of the Rap1 GTPase by the B cell antigen receptor.
- 46 *J. Biol. Chem.* **273**: 29218–29223.
- 47
- 48 54. Altschuler D.L., S.N. Peterson, M.C. Ostrowski, *et al.* 1995. Cyclic AMP-dependent activation of Rap1b. *J.*
- 49 *Biol. Chem.* **270**: 10373–10376.
- 50
- 51 55. Tsygankova O.M., A. Saavedra, J.F. Rebhun, *et al.* 2001. Coordinated regulation of Rap1 and thyroid
- 52 differentiation by cyclic AMP and protein kinase A. *Mol. Cell. Biol.* **21**: 1921–1929.
- 53
- 54 56. Vossler M.R., H. Yao, R.D. York, *et al.* 1997. cAMP activates MAP kinase and Elk-1 through a B-Raf- and
- 55 Rap1-dependent pathway. *Cell* **89**: 73–82.
- 56
- 57
- 58
- 59
- 60

- 1  
2 57. Zanassi P., M. Paolillo, A. Feliciello, *et al.* 2001. cAMP-dependent protein kinase induces cAMP-response  
3 element-binding protein phosphorylation via an intracellular calcium release/ERK-dependent pathway in  
4 striatal neurons. *J. Biol. Chem.* **276**: 11487–11495.  
5  
6 58. Reedquist K.A., E. Ross, E.A. Koop, *et al.* 2000. The small GTPase, Rap1, mediates CD31-induced integrin  
7 adhesion. *J. Cell Biol.* **148**: 1151–1158.  
8  
9 59. Caron E., A.J. Self & A. Hall. 2000. The GTPase Rap1 controls functional activation of  $\alpha$ M $\beta$ 2 macrophage by  
10 LPS and other inflammatory mediators. *Curr. Biol.* **10**: 974–978.  
11  
12 60. Katagiri K., M. Hattori, N. Minato, *et al.* 2000. Rap1 is a potent activation signal for leukocyte function-  
13 associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. *Mol. Cell. Biol.* **20**:  
14 1956–69.  
15  
16 61. Seastone D.J., L. Zhang, G. Buczynski, *et al.* 1999. The small Mr Ras-like GTPase Rap1 and the  
17 phospholipase C pathway act to regulate phagocytosis in Dictyostelium discoideum. *Mol. Biol. Cell* **10**: 393–  
18 406.  
19  
20 62. Jeon T.J., D.J. Lee, S. Merlot, *et al.* 2007. Rap1 controls cell adhesion and cell motility through the regulation  
21 of myosin II. *J Cell Biol* **176**: 1021–1033.  
22  
23 63. Kondo H., J. Guo & F.R. Bringhurst. 2002. Cyclic adenosine monophosphate/protein kinase A mediates  
24 parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and  
25 expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. *J. Bone Miner. Res.* **17**: 1667–  
26 1679.  
27  
28 64. Price L.S., J. Leng, M.A. Schwartz, *et al.* 1998. Activation of Rac and Cdc42 by Integrins Mediates Cell  
29 Spreading. *Mol. Biol. Cell* **9**: 1863–1871.  
30  
31 65. Koch A.E., H.P. Castro-Rueda, G.K. Kenneth, *et al.* 2007. Differential expression of the FAK family kinases  
32 in rheumatoid arthritis and osteoarthritis synovial tissues. *Arthritis Res. Ther.* **9**:  
33  
34 66. Mediero A., M. Perez-Aso & B.N. Cronstein. 2014. Activation of EPAC1/2 is essential for osteoclast  
35 formation by modulating NF $\kappa$ B nuclear translocation and actin cytoskeleton rearrangements. *FASEB J.* **28**:  
36 4901–4913.  
37  
38 67. Hynes R.O. 2002. Integrins: Bidirectional, allosteric signaling machines. *Cell* **110**: 673–687.  
39  
40 68. Nakamura I., L.T. Duong, S.B. Rodan, *et al.* 2007. Involvement of  $\alpha$ v $\beta$ 3 integrins in osteoclast function. *J.*  
41 *Bone Miner. Metab.* **25**: 337–344.  
42  
43 69. Horton M.A. 1997. The alpha v beta 3 integrin “vitronectin receptor.” *Int J Biochem Cell Biol* **29**: 721–725.  
44  
45 70. Flores M.E., M. Norgård, D. Heinegård, *et al.* 1992. RGD-directed attachment of isolated rat osteoclasts to  
46 osteopontin, bone sialoprotein, and fibronectin. *Exp. Cell Res.* **201**: 526–530.  
47  
48 71. Helfrich M.H., S.A. Nesbitt, P.T. Lakkakorpi, *et al.* 1996.  $\beta$ 1-integrins and osteoclast function: involvement in  
49 collagen recognition and bone resorption. *Bone* **19**: 317–328.  
50  
51 72. Nakamura I., N. Takahashi, T. Sasaki, *et al.* 1996. Chemical and physical properties of the extracellular matrix  
52 are required for the actin ring formation in osteoclasts. *J Bone Min. Res* **11**: 1873–1879.  
53  
54 73. Duong L.T., P. Lakkakorpi, I. Nakamura, *et al.* 2000. Integrins and signaling in osteoclast function. *Matrix*  
55 *Biol.* **19**: 97–105.  
56  
57  
58  
59  
60

- 1  
2 74. Wennerberg K., L. Lohikangas, D. Gullberg, *et al.* 1996.  $\beta$ 1 integrin-dependent and -independent  
3 polymerization of fibronectin. *J Cell Biol.* **132**: 227–238.  
4
- 5 75. Fukunaga T., W. Zou, J.T. Warren, *et al.* 2014. Vinculin regulates osteoclast function. *J. Biol. Chem.* **289**:  
6 13554–13564.  
7
- 8 76. Das M., S. Subbayya Ithychanda, J. Qin, *et al.* 2014. Mechanisms of talin-dependent integrin signaling and  
9 crosstalk. *Biochim. Biophys. Acta - Biomembr.* **1838**: 579–588.  
10
- 11 77. Schlaepfer D.D. & T. Hunter. 1998. Integrin signalling and tyrosine phosphorylation: Just the FAKs? *Trends*  
12 *Cell Biol.* **8**: 151–157.  
13
- 14 78. Harburger D.S. & D.A. Calderwood. 2009. Integrin signalling at a glance. *J. Cell Sci.* **122**: 1472–1472.  
15
- 16 79. Zou W., T. Izawa, T. Zhu, *et al.* 2013. Talin1 and Rap1 are critical for osteoclast function. *Mol. Cell. Biol.* **33**:  
17 830–844.  
18
- 19 80. Bauer D.C., A. Schwartz, L. Palermo, *et al.* 2014. Fracture prediction after discontinuation of 4 to 5 years of  
20 Alendronate therapy: The FLEX study. *JAMA Intern. Med.* **174**: 1126–1134.  
21
- 22 81. Eastell R., S. Boonen, F. Cosman, *et al.* 2015. Relationship between pretreatment rate of bone loss and bone  
23 density response to once-yearly ZOL: HORIZON-PFT extension study. *J. Bone Miner. Res.* **30**: 570–574.  
24
- 25 82. Coxon F.P., M.H. Helfrich, R. Van't Hof, *et al.* 2000. Protein geranylgeranylation is required for osteoclast  
26 formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. *J. Bone Miner. Res.* **15**: 1467–  
27 1476.  
28
- 29 83. Frith J.C. & M.J. Rogers. 2003. Antagonistic effects of different classes of bisphosphonates in osteoclasts and  
30 macrophages in vitro. *J Bone Min. Res* **18**: 204–212.  
31
- 32 84. Roelofs A.J., K. Thompson, S. Gordon, *et al.* 2006. Molecular mechanisms of action of bisphosphonates:  
33 current status. *Clin. Cancer Res.* **12**: 6222s–6230s.  
34
- 35 85. Coxon F.P. & M.J. Rogers. 2003. The role of prenylated small GTP-binding proteins in the regulation of  
36 osteoclast function. *Calcif. Tissue Int.* **72**: 80–84.  
37
- 38 86. Fisher J.E., M.J. Rogers, J.M. Halasy, *et al.* 1999. Alendronate mechanism of action: geranylgeraniol, an  
39 intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and  
40 kinase activation in vitro. *Proc. Natl. Acad. Sci.* **96**: 133–138.  
41
- 42 87. Van Beek E., C. Löwik, G. Van Der Pluijm, *et al.* 1999. The role of geranylgeranylation in bone resorption and  
43 its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of  
44 nitrogen-containing bisphosphonates. *J. Bone Miner. Res.* **14**: 722–729.  
45
- 46 88. Pazianas M., J. Compston & C.L.-H. Huang. 2010. Atrial fibrillation and bisphosphonate therapy. *J. Bone*  
47 *Miner. Res.* **25**: 2–10.  
48
- 49 89. Bhuriya R., M. Singh, J. Molnar, *et al.* 2010. Bisphosphonate use in women and the risk of atrial fibrillation: A  
50 systematic review and meta-analysis. *Int. J. Cardiol.* **142**: 213–217.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Figure legends

### Figure 1. Osteoclast motility properties.

(A) Measurement by overlaying cell margin outlines obtained at successive 2 min intervals (numbered 1-4) in time,  $t$ , in order to measure changes in normalised cell spread area  $\rho = A(t)/A(t_0)$  and protrusion  $\Delta p$  and retraction  $\Delta r$  activity at the cell margin, used to derive an index for cell motility  $\mu = (\Delta p + \Delta r)/A(t)$ . The effect of (B) 300 pM human calcitonin (hCT) (C) 20 mM extracellular  $[Ca^{2+}]$  and (D) 250 nM amylin applied at  $t = 0$ , on motility and cell spread area. Note that calcitonin affects both but extracellular  $[Ca^{2+}]$  and amylin selectively influence the time course of one of the two parameters  $\mu$  or  $\rho$  (reproduced by permission from <sup>10</sup>).

### Figure 2. Basic organization of Epac isoforms.

In Epac1 the regulatory region contains membrane localizing dishevelled-Egl-10-Pleckstrin (DEP) and regulatory, cyclic mononucleotide-binding (CNB) domains. Epac2 further includes an additional CNB domain N-terminal to the DEP domain. The regulatory domains are joined via a Ras exchange motif (REM) and a ras association (RA) domain to the Cdc25 homology domain (CDC25HD) responsible for GEF activity. The isoform related to Epac, Repac, only includes the catalytic region.

### Figure 3. Rap1 activation by the Epac signalling system

Activation of Epac by the direct action of cAMP (A) enhancing the guanine nucleotide-exchange factor (GEF) function of Epac. (B) The increased exchange of GDP for GTP binding results in activation of the Ras-proximate-1 (Rap1).

### Figure 4. Consequences of osteoclast integrin activation

Following (A) activation by Rap1,  $\alpha_v\beta_3$  integrins (B) mediate osteoclast adhesion to the bone surface by interacting with extracellular bone matrix proteins containing RGD (Arg-Gly-Asp) sequences, including vitronectin, osteopontin and bone sialoprotein. Integrin-ligand binding induces receptor clustering causing formation of focal adhesion contacts, recruitment of cytoskeletal molecules with organisation of intracellular cytoskeletal complexes leading to changes in cell shape, spreading and motility. Integrins also mediate transmembrane transduction of signals in both inside-out and outside-in directions relating organization of the actin network and the composition of the focal adhesions, through the cytoskeletal protein talin which links integrins to the actin cytoskeleton. Finally, a wide range of phosphatidylinositol 3-kinase, c-Src, PYK2 and p130<sup>cas</sup> signaling pathways are  $\alpha_v\beta_3$  integrin-dependent.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

190x142mm (300 x 300 DPI)

Fig. 2




Figure 2

190x142mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3

190x142mm (300 x 300 DPI)

Fig. 4




Figure 4

190x142mm (300 x 300 DPI)